- Treatment of hepatitis B and C
- Clinical trials in viral hepatitis
- Management of antiviral-resistant hepatitis B
J Pediatr Surg. 2018 Sep 09;:
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Dig Dis Sci. 2018 Aug 22;:
The north-south and east-west gradient in colorectal cancer risk: a look at the distribution of modifiable risk factors and incidence across Canada.
Curr Oncol. 2018 Jun;25(3):231-235
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.
Clin Gastroenterol Hepatol. 2018 Jun 19;:
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
J Hepatol. 2018 Apr;68(4):672-681
Measuring patient-reported outcomes to improve cancer care in Canada: an analysis of provincial survey data.
Curr Oncol. 2018 Apr;25(2):176-179
J Glaucoma. 2018 Apr 02;:
Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B.
J Hepatol. 2017 Nov 02;:
The experience of patients with cancer during diagnosis and treatment planning: a descriptive study of Canadian survey results.
Curr Oncol. 2017 Oct;24(5):332-337
Clinical Researcher, Toronto General Hospital Research Institute (TGHRI)
Assistant Professor, Department of Medicine, University of Toronto
Site Director, Gastroenterology Education, Toronto General Hospital
GI Education Coordinator for General Internal Medicine, UHN and Mount Sinai Hospital